Investigating N-arylpyrimidinamine (NAPA) compounds as early-stage inhibitors against human cytomegalovirus.
Parsons AJ, Ophir SI, Gardner TJ, Paredes JC, Stein KR, Kwasny SM, Cardinale SC, Torhan M, Prichard MN, James SH, Atanasoff KE, G-Dayanandan N, Bowlin TL, Opperman TJ, Tortorella D.
Parsons AJ, et al. Among authors: cardinale sc.
Antiviral Res. 2023 Jan;209:105474. doi: 10.1016/j.antiviral.2022.105474. Epub 2022 Nov 26.
Antiviral Res. 2023.
PMID: 36511318
Free PMC article.